Economic implications of early treatment of migraine with sumatriptan tablets
- 1 February 2001
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 23 (2) , 284-291
- https://doi.org/10.1016/s0149-2918(01)80011-4
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Treatment of Mild Headache in Disabled Migraine Sufferers: Results of the Spectrum StudyHeadache: The Journal of Head and Face Pain, 2000
- Cost-Benefit Analysis of Sumatriptan Tablets versus Usual Therapy for Treatment of MigrainePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
- Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trialsClinical Therapeutics, 2000
- Acute Migraine Therapy: Do Doctors Understand What Patients With Migraine Want From Therapy?Headache: The Journal of Head and Face Pain, 1999
- Sumatriptan Injection Reduces Productivity Loss During a Migraine AttackArchives of internal medicine (1960), 1998
- Efficacy and Safety of Sumatriptan Tablets (25 mg, 50 mg, and 100 mg) in the Acute Treatment of Migraine: Defining the Optimum Doses of Oral SumatriptanHeadache: The Journal of Head and Face Pain, 1998
- Economic Evaluation of Oral Sumatriptan Compared with Oral Caffeine/Ergotamine for MigrainePharmacoEconomics, 1997
- Comparing Dihydroergotamine Mesylate and Sumatriptan in the Management of Acute MigrainePharmacoEconomics, 1996